Table 1 HRMS detects sustained increases in monoclonal light chain before standard methods do.

PID	Arm	BOR (INV)	BOR cycle	Clinical progression method by IMWG	Progression cycle by IMWG	Last cycle measured by data cut-off	Sustained M-protein increase by HRMS	Last cycle measured by HRMS	Difference in cycles, HRMS vs standard method^a	Notes
001	EPd	VGPR	C7	NA	NA	C26	ND	C26		No documented progression
031	Pd	VGPR	C9	Plasmacytoma	C24	C23	C20	C23	4	C24 was an assessment visit, not a treatment cycle. Progression by SPEP at assessment visit C25
044	EPd	VGPR	C4	UPEP	C9	C9	C6	C9	3
058	EPd	CR^b	C25-C26^c	NA	NA	C27	ND	C39		No documented progression
060	EPd	VGPR	C4	UPEP	C18	C19	C7	C19	11
084	EPd	VGPR	C9	Plasmacytoma	C18	C17	C15	C17	3	No progression by SPEP/UPEP
087	Pd	VGPR	C2	sFLC	C11	C15	C8	C15	3	No progression by SPEP/UPEP
097	Pd	CR^b	C11	NA	NA	C24	ND	C36		No documented progression
100	EPd	CR	C13	SPEP	C22	C24	C14	C24	8
101	Pd	VGPR	C10	sFLC	C18	C19	ND	C19		No progression by SPEP/UPEP
103	EPd	sCR	C5	NA	NA	C24	ND	C28		No documented progression
109	EPd	VGPR	C14	NA	NA	C24	ND	C35		No documented progression
116	EPd	VGPR	C8	NA	NA	C23	C14	C35	9	No documented progression
121	EPd	CR	C4	UPEP	C15	C17	C8	C17	7
122	Pd	CR^b	C7	NA	NA	C22	C21	C31		No documented progression
133	EPd	VGPR	C10	NA	NA	C22	C31	C34		No documented progression
151	EPd	VGPR	C6	NA	NA	C20	C15	C25	5	No documented progression

The time point (in treatment cycles) of patient relapse, as well as method used to determine clinical relapse, is shown together with the time point where a sustained increase in monoclonal light chain levels is detected by HRMS.
PID patient identification, BOR best overall response, INV investigator, IMWG International Myeloma Working Group, HRMS high-resolution mass spectrometry.
^aAs determined by the date of data cut-off.
^bNo bone marrow available to confirm CR.
^cBOR documented between C25 and C26.

Quick links

Search